65,437 trials
Migraine
Primary: Change in Frequency of Migraine Days During the Last 28 Day Interval of the Treatment Period as Compared to the 28 Day Baseline Period. — 4.5 days
Esophageal Neoplasm
Primary: Pulmonary Gas Exchange During and After Esophageal Carcinoma Surgery (PaO2/FiO2 Ratio) — 345.01; 330.11; 315.51; 307.11 mmHg — p=0.410
Carcinoma, Renal Cell
Primary: Objective Response Rate (ORR) - Percentage of Participants With Objective Response — 53.6; 33.9; 59.3; 48.4 Percentage of Participants — p=0.0189
Suspected Eosinophilic Esophagitis
Primary: Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) — 69; 79 Percent Change
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Total Nasal Symptom Score (TNSS) Averaged During 3 Hours of Exposure — 1.17; 1.18 score on a scale — p=0.913
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Neutrophil Count in Induced Sputum at Week 12 — 1.35; -6.00 ratio (%) — p=0.5146
Perennial Allergic Rhinitis · PAR
Primary: The Change in Serum Cortisol Area Under the Curve (AUC) From Time 0 to 24 Hours (0-24), Calculated Using a Trapezoidal Rule, From Baseline to the End of the 6 Week…
Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: Proportion of Patients Who do Not Demonstrate Disease Progression
Prostate Cancer
Primary: Area Under the Curve of Testosterone Serum Concentration Between D1 and D85 (AUC1-85d). — 4.24; 4.23 log(ng*day/mL)
Low Back Pain · Pain · Pain, Intractable
Primary: Roland-Morris Disability Questionnaire — 13.7; 14.0; 12.1; 10.6 scores on a scale
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 0; 0 participants
Lung Cancer, Non-Small Cell
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator (INV) — 11.7; 11.4 Weeks — p=0.5197
Attention Deficit/Hyperactivity Disorder
Primary: Number of Participants With Adverse Events, Serious Adverse Events and Deaths. — 208; 2; 0 participants
Bone Mineral Density · Bone Strength
Primary: Percent Change in Total Bone Mineral Content (BMC) Per Height Compared Between Intervention and Placebo Groups — 2.72; 3.96 % change in grams/cm — p=0.69
Obesity
Primary: Time for Intubation — 9; 7.3 seconds